Daptomycin; First And Only Member Of Cyclic Lipopeptide Antibiotics

Daptomycin, is currently the first and only member of a new age antibiotics class labeled as cyclic lipopeptides. The spectrum of its effectiveness is limited with gram positive aerobe and anaerobe bacteria. It is effective against; staphylococci including methicillin resistant S.aureus (MRSA), vancomycin intermediately sensitive S.aureus (VISA), vancomycin resistant S.aureus (VRSA), enterococci including E.faecalis and E.faecium, and penicillin resistance streptococci including S.pneumoniae. Daptomycin, first used in the world in 2003, was licensed in our country in 2009. The clinical indications for daptomycin use are the same with other countries; namely, complicated skin and soft tissues infections, and S.aureus bacteremia and S.aureus right sided endocarditis.